Identification

Name
Enoxaparin
Accession Number
DB01225  (APRD00068)
Type
Small Molecule
Groups
Approved
Description

Enoxaparin is a low molecular weight heparin. Enoxaparin is used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. Factor Xa catalyzes the conversion of prothrombin to thrombin, so enoxaparin's inhibition of this process results in decreased thrombin and ultimately the prevention of fibrin clot formation. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Synonyms
  • Enoxaparin sodium
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Enoxaparin sodiumInjection100 mg/mLSubcutaneousCardinal Health2015-02-20Not applicableUs
Enoxaparin sodiumInjection100 mg/mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin sodiumInjection100 mg/mLSubcutaneousCardinal Health2015-02-20Not applicableUs
Enoxaparin sodiumInjection40 mg/.4mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin sodiumInjection300 mg/3mLSubcutaneousFresenius Kabi2015-02-20Not applicableUs
Enoxaparin sodiumInjection150 mg/mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin sodiumInjection100 mg/mLSubcutaneousCardinal Health2015-02-20Not applicableUs
Enoxaparin sodiumInjection80 mg/.8mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin sodiumInjection150 mg/mLSubcutaneousFresenius Kabi2015-02-20Not applicableUs
Enoxaparin sodiumInjection100 mg/mLSubcutaneousCardinal Health2015-02-20Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection80 mg/.8mLSubcutaneousWatson Pharma, Inc.2012-01-27Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousSandoz2010-07-23Not applicableUs
Enoxaparin SodiumInjection, solution60 mg/.6mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2014-09-26Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection150 mg/mLSubcutaneousSandoz2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
International/Other Brands
Clexane
Categories
UNII
8NZ41MIK1O
CAS number
9005-49-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.

Structured Indications
Pharmacodynamics

Enoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from 3800 to 5000 daltons. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant which has antithrombotic properties. Enoxaparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Enoxaparin acts at multiple sites in the normal coagulation system. Small amounts of enoxaparin in combination with antithrombin III (enoxaparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of enoxaparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.

Mechanism of action

The mechanism of action of enoxaparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of enoxaparin is well correlated to the inhibition of factor Xa. Enoxaparin interacts with Antithrombin III, Prothrombin and Factor X. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa.

TargetActionsOrganism
AAntithrombin-III
potentiator
Human
ACoagulation factor X
inhibitor
Human
Absorption

Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given subcutaneously, based on anti-Factor Xa activity is approximately 100% in healthy volunteers.

Volume of distribution
  • 4.3 L
Protein binding

80% bound-albumin

Metabolism

Undergoes desulfation and polymerization via the liver

Route of elimination

Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency. Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.

Half life

4.5 hours

Clearance
Not Available
Toxicity

Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabAbciximab may increase the anticoagulant activities of Enoxaparin.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
AcemetacinAcemetacin may increase the anticoagulant activities of Enoxaparin.Approved, Experimental, Investigational
AcenocoumarolEnoxaparin may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Enoxaparin.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
AliskirenEnoxaparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Enoxaparin.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Enoxaparin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Enoxaparin.Approved
AltrenogestThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Enoxaparin.Investigational
AmilorideEnoxaparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Enoxaparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Enoxaparin.Approved
AncrodEnoxaparin may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Enoxaparin.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Enoxaparin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Enoxaparin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Enoxaparin.Approved
Antithrombin III humanEnoxaparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Enoxaparin.Approved
ApocyninApocynin may increase the anticoagulant activities of Enoxaparin.Investigational
ApremilastApremilast may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
AprotininThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Enoxaparin.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Enoxaparin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Enoxaparin.Approved
Azilsartan medoxomilEnoxaparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Enoxaparin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Enoxaparin.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
BenazeprilEnoxaparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Enoxaparin.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Enoxaparin.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Enoxaparin.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Enoxaparin.Approved
BeraprostBeraprost may increase the anticoagulant activities of Enoxaparin.Investigational
BevoniumBevonium may increase the anticoagulant activities of Enoxaparin.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Enoxaparin.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Enoxaparin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Enoxaparin.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Enoxaparin.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Enoxaparin.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Enoxaparin.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Enoxaparin.Investigational
CanagliflozinEnoxaparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanEnoxaparin may increase the hyperkalemic activities of Candesartan.Experimental
Candesartan cilexetilEnoxaparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
CandoxatrilEnoxaparin may increase the hyperkalemic activities of Candoxatril.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Enoxaparin.Approved
CaptoprilEnoxaparin may increase the hyperkalemic activities of Captopril.Approved
CarprofenCarprofen may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Enoxaparin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
CertoparinEnoxaparin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Enoxaparin.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Enoxaparin.Approved
CilazaprilEnoxaparin may increase the hyperkalemic activities of Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Enoxaparin.Approved
Citric AcidEnoxaparin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Enoxaparin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Enoxaparin.Approved, Nutraceutical
CloricromenCloricromen may increase the anticoagulant activities of Enoxaparin.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Enoxaparin.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Enoxaparin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Enoxaparin.Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Enoxaparin.Investigational
Dabigatran etexilateEnoxaparin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Enoxaparin.Experimental
DalteparinEnoxaparin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEnoxaparin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanEnoxaparin may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
DelaprilEnoxaparin may increase the hyperkalemic activities of Delapril.Experimental
DemegestoneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Enoxaparin.Investigational
DesirudinEnoxaparin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Enoxaparin.Investigational
DesogestrelThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Desogestrel.Approved
DextranEnoxaparin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Enoxaparin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Enoxaparin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Enoxaparin may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Enoxaparin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Enoxaparin.Approved, Investigational
DienogestThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Enoxaparin.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Enoxaparin.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Enoxaparin.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Enoxaparin.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Enoxaparin.Approved
DitazoleDitazole may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Enoxaparin.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Enoxaparin.Investigational
DydrogesteroneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Enoxaparin.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Enoxaparin.Approved
EnalaprilEnoxaparin may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatEnoxaparin may increase the hyperkalemic activities of Enalaprilat.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Enoxaparin.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Enoxaparin.Approved
EplerenoneEnoxaparin may increase the hyperkalemic activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Enoxaparin.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Enoxaparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Enoxaparin.Approved
EprosartanEnoxaparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Enoxaparin.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Enoxaparin.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Enoxaparin.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Enoxaparin.Approved
EstroneEstrone may decrease the anticoagulant activities of Enoxaparin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Enoxaparin.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Enoxaparin.Approved
Ethyl biscoumacetateEnoxaparin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
exisulindexisulind may increase the anticoagulant activities of Enoxaparin.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Enoxaparin.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Enoxaparin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Enoxaparin.Approved
FentiazacFentiazac may increase the anticoagulant activities of Enoxaparin.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Enoxaparin.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Enoxaparin.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Enoxaparin.Investigational
FimasartanEnoxaparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
FluindioneEnoxaparin may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Enoxaparin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Enoxaparin.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
FondaparinuxEnoxaparin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
ForasartanEnoxaparin may increase the hyperkalemic activities of Forasartan.Experimental
FosinoprilEnoxaparin may increase the hyperkalemic activities of Fosinopril.Approved
GabexateEnoxaparin may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Enoxaparin.Investigational
GestodeneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Enoxaparin.Experimental
HeminHemin may increase the anticoagulant activities of Enoxaparin.Approved
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Enoxaparin.Experimental
HeparinHeparin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Enoxaparin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Enoxaparin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Enoxaparin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Enoxaparin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Enoxaparin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Enoxaparin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Enoxaparin.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Enoxaparin.Approved, Nutraceutical
IdraparinuxEnoxaparin may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Enoxaparin.Investigational
IloprostIloprost may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
ImidaprilEnoxaparin may increase the hyperkalemic activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Enoxaparin.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Enoxaparin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Enoxaparin.Withdrawn
IrbesartanEnoxaparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Enoxaparin.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Enoxaparin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Enoxaparin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Enoxaparin.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Enoxaparin.Approved
LetaxabanEnoxaparin may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Enoxaparin.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Enoxaparin.Experimental
LisinoprilEnoxaparin may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Enoxaparin.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Enoxaparin.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
LosartanEnoxaparin may increase the hyperkalemic activities of Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Enoxaparin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Enoxaparin.Approved
Megestrol acetateThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MelagatranEnoxaparin may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Enoxaparin.Approved
MestranolMestranol may decrease the anticoagulant activities of Enoxaparin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Enoxaparin.Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Enoxaparin.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Methylestrenolone.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Enoxaparin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Enoxaparin.Investigational
MoexiprilEnoxaparin may increase the hyperkalemic activities of Moexipril.Approved
MofebutazoneMofebutazone may increase the anticoagulant activities of Enoxaparin.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Enoxaparin.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Enoxaparin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Enoxaparin.Approved
NadroparinEnoxaparin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Enoxaparin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Enoxaparin.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Enoxaparin.Approved
NifenazoneNifenazone may increase the anticoagulant activities of Enoxaparin.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Enoxaparin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Enoxaparin.Investigational
NomegestrolThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Obinutuzumab.Approved
OlmesartanEnoxaparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Enoxaparin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Enoxaparin.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatEnoxaparin may increase the hyperkalemic activities of Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Enoxaparin.Approved, Nutraceutical
OrgoteinOrgotein may increase the anticoagulant activities of Enoxaparin.Vet Approved
OtamixabanEnoxaparin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Enoxaparin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Enoxaparin.Investigational
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Enoxaparin.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Enoxaparin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Enoxaparin.Investigational
Pentaerythritol TetranitrateEnoxaparin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Enoxaparin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PerindoprilEnoxaparin may increase the hyperkalemic activities of Perindopril.Approved
PhenindionePhenindione may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Enoxaparin.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Enoxaparin.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Enoxaparin.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Enoxaparin.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Enoxaparin.Approved
ProgesteroneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Enoxaparin.Experimental
PromegestoneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Enoxaparin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Enoxaparin.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Enoxaparin.Experimental
Protein CEnoxaparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanEnoxaparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEnoxaparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Enoxaparin.Investigational
QuinaprilEnoxaparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Enoxaparin.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Enoxaparin.Investigational
RamiprilEnoxaparin may increase the hyperkalemic activities of Ramipril.Approved
RescinnamineEnoxaparin may increase the hyperkalemic activities of Rescinnamine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Enoxaparin.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Enoxaparin.Approved
ReviparinEnoxaparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Enoxaparin.Approved
RivaroxabanEnoxaparin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Enoxaparin.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
SacubitrilEnoxaparin may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Enoxaparin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Enoxaparin.Approved
SaprisartanEnoxaparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinEnoxaparin may increase the hyperkalemic activities of Saralasin.Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Enoxaparin.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Enoxaparin.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Enoxaparin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Enoxaparin.Approved
SemapimodSemapimod may increase the anticoagulant activities of Enoxaparin.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Enoxaparin.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Enoxaparin.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
SpiraprilEnoxaparin may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneEnoxaparin may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Enoxaparin.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Enoxaparin.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Enoxaparin.Approved
SulindacSulindac may increase the anticoagulant activities of Enoxaparin.Approved
SulodexideEnoxaparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Enoxaparin.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Enoxaparin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Enoxaparin.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Enoxaparin.Investigational
TasosartanEnoxaparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanEnoxaparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemocaprilEnoxaparin may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Enoxaparin.Approved
TenidapTenidap may increase the anticoagulant activities of Enoxaparin.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Enoxaparin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Enoxaparin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Enoxaparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Enoxaparin.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Enoxaparin.Approved
TiboloneTibolone may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Enoxaparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Enoxaparin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Enoxaparin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Enoxaparin.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Enoxaparin.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Enoxaparin.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Enoxaparin.Approved
TolmetinTolmetin may increase the anticoagulant activities of Enoxaparin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Tositumomab.Approved, Investigational
TrandolaprilEnoxaparin may increase the hyperkalemic activities of Trandolapril.Approved
TranilastTranilast may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Enoxaparin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
TriamtereneEnoxaparin may increase the hyperkalemic activities of Triamterene.Approved
TribenosideTribenoside may increase the anticoagulant activities of Enoxaparin.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Enoxaparin.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Enoxaparin.Approved
TroxerutinEnoxaparin may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Enoxaparin.Investigational, Withdrawn
ValsartanEnoxaparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Enoxaparin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Enoxaparin.Approved
WarfarinWarfarin may increase the anticoagulant activities of Enoxaparin.Approved
XimelagatranEnoxaparin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Enoxaparin.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Withdrawn
ZofenoprilEnoxaparin may increase the hyperkalemic activities of Zofenopril.Experimental
ZomepiracZomepirac may increase the anticoagulant activities of Enoxaparin.Withdrawn
Food Interactions
  • Avoid danshen, dong quai, evening primrose oil, gingko, policosanol, willow bark

References

Synthesis Reference

Jorgen I. Nielsen, "Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin." U.S. Patent US5106734, issued May, 1981.

US5106734
General References
Not Available
External Links
Human Metabolome Database
HMDB14551
KEGG Drug
D07510
PubChem Substance
46507450
ChemSpider
751
ChEMBL
CHEMBL1201685
Therapeutic Targets Database
DAP000616
PharmGKB
PA449463
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Enoxaparin_sodium
ATC Codes
B01AB05 — Enoxaparin
AHFS Codes
  • 20:12.04.16 — Heparins
FDA label
Download (1.44 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedPreventionDeep Venous Thrombosis / Prophylaxis of Pulmonary embolism1
0RecruitingTreatmentAntiphospholipid Syndrome in Pregnancy / Pregnancy Loss1
1CompletedNot AvailableClexane is Administered to Healthy Volunteers1
1CompletedNot AvailableEnoxaparin Sodium is Administered to Healthy Volunteers1
1CompletedOtherHealthy Volunteers1
1CompletedPreventionBMI >30 kg/m2 / Complications; Cesarean Section / Obesity, Morbid / Postpartum Deep Phlebothrombosis / Pregnancy / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
1CompletedTreatmentAcute Coronary Syndromes (ACS)1
1CompletedTreatmentHaemorrhage1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentInfertilities1
1CompletedTreatmentThrombosis1
1RecruitingNot AvailableVenous Thromboembolism1
1Unknown StatusTreatmentHealthy Volunteers1
1Unknown StatusTreatmentTraumatic Brain Injury (TBI) / Venous Thromboembolism1
1, 2CompletedOtherHealthy Volunteers1
1, 2CompletedTreatmentDeep Venous Thrombosis1
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentAntithrombotic1
1, 2RecruitingTreatmentMalignant Lymphomas1
2CompletedNot AvailableStaphylococcus Aureus Bacteraemia1
2CompletedPreventionAdvanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer1
2CompletedPreventionArthroplasty, Replacement, Hip / Deep Vein Thrombosis (DVT) / Embolism and Thrombosis / Thromboembolism / Thrombosis / Venous Thromboembolism1
2CompletedPreventionColorectal Cancers / Hepatic Metastases / Irradiation Damage / Radiation Induced Liver Disease1
2CompletedPreventionKnee Replacement Surgery1
2CompletedPreventionKnee Replacement Surgery / Total Hip Replacement1
2CompletedPreventionPrevention / Thromboembolism1
2CompletedPreventionThromboembolism1
2CompletedPreventionThrombosis, Venous1
2CompletedPreventionTotal Knee Replacement Surgery1
2CompletedPreventionVenous Thromboembolism6
2CompletedTreatmentCatheter-Related Infections / Catheter-related Occlusion / Central Venous Catheterization / Childhood Cancers / Deep Vein Thrombosis (DVT)1
2CompletedTreatmentRecurrent Abortion1
2CompletedTreatmentSubmassive Pulmonary Embolism1
2CompletedTreatmentVulvodynia1
2Not Yet RecruitingOtherDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
2Not Yet RecruitingTreatmentCerebral Venous Thrombosis1
2RecruitingOtherDeep Venous Thrombosis / Prophylaxis of Pulmonary embolism / Reconstructive Surgery / Venous Thromboembolism1
2RecruitingPreventionDeep Venous Thrombosis1
2RecruitingPreventionGynecologic Cancers / Venous Thromboembolism1
2RecruitingPreventionKnee Arthroplasty, Total1
2RecruitingTreatmentThrombosis1
2RecruitingTreatmentVenous Thormboembolism1
2TerminatedPreventionPortal Vein Thrombosis / Splenic Vein Thrombosis1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2Unknown StatusPreventionEmbolic Stroke1
2Unknown StatusSupportive CareCancers / Deep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Thrombosis / Venous Thromboembolism1
2WithdrawnTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2, 3CompletedPreventionArthroplasty, Replacement, Hip / Venous Thromboembolism1
2, 3CompletedPreventionPercutaneous Coronary Intervention1
2, 3CompletedPreventionThrombosis, Venous1
2, 3CompletedPreventionProphylaxis of Pulmonary embolism / Thrombosis, Venous1
2, 3CompletedPreventionVenous Thromboembolism2
2, 3CompletedTreatmentMalignant Neoplasm of Pancreas1
2, 3CompletedTreatmentMyocardial Infarction (MI)1
3CompletedNot AvailableCancers1
3CompletedPreventionAcute ST-Segment Elevation / Myocardial Infarction (MI)1
3CompletedPreventionArthroplasty, Replacement, Hip1
3CompletedPreventionArthroplasty, Replacement, Hip / Thromboembolism1
3CompletedPreventionArthroplasty, Replacement, Knee / Thromboembolism2
3CompletedPreventionDeep Vein Thrombosis (DVT)1
3CompletedPreventionDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism2
3CompletedPreventionHigh Risk Pregnant Women / Placental Insufficiency / Preeclampsia1
3CompletedPreventionNeoplasms, Abdominal1
3CompletedPreventionPreeclampsia1
3CompletedPreventionPrevention / Venous Thromboembolism2
3CompletedPreventionProphylaxis of Pulmonary embolism / Thrombosis, Venous1
3CompletedPreventionVenous Thromboembolism12
3CompletedPreventionVenous Thromboembolism (VTE)1
3CompletedPreventionProphylaxis of Pulmonary embolism / Venous Thromboembolism1
3CompletedSupportive CareGastrooesophageal Cancer / Malignant Neoplasm of Stomach1
3CompletedTreatmentAcute Myocardial Infarction (AMI)1
3CompletedTreatmentDeep Vein Thrombosis (DVT)1
3CompletedTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism1
3CompletedTreatmentHip Fractures1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3CompletedTreatmentMyocardial Infarction (MI)3
3CompletedTreatmentMyocardial Infarction (MI) / Myocardial Ischemia / Unstable Angina (UA)1
3CompletedTreatmentMyocardial Infarction (MI) / Thromboembolism1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3CompletedTreatmentPrevention / Venous Thromboembolism1
3CompletedTreatmentPrimary PCI - STEMI1
3CompletedTreatmentSystemic Embolism / Thrombosis1
3CompletedTreatmentThromboprophylaxis in Hospitalized Obese Patients1
3CompletedTreatmentThrombosis, Venous2
3CompletedTreatmentVenous Thromboembolism1
3CompletedTreatmentProphylaxis of Pulmonary embolism1
3Not Yet RecruitingPreventionHCC1
3Not Yet RecruitingPreventionTunnelled Hemodialysis Catheter Infection1
3RecruitingPreventionBlood Clots / Traumas1
3RecruitingPreventionDeep Venous Thrombosis / Hemorrhagic Strokes / Venous Thromboembolism1
3RecruitingPreventionNon-major Orthopaedic Surgery1
3RecruitingPreventionVenous Thromboembolism1
3RecruitingTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism / Venous Thromboembolism (VTE)1
3RecruitingTreatmentIntrauterine Growth Retardation1
3SuspendedPreventionMalignant Female Reproductive System Neoplasm1
3TerminatedPreventionVenous Thromboembolism2
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3TerminatedTreatmentNeoplasms / Venous Thromboembolism1
3TerminatedTreatmentNon ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina (UA)1
3TerminatedTreatmentProphylaxis of Pulmonary embolism1
3WithdrawnTreatmentAsymptotic Venous Thrombosis1
4Active Not RecruitingPreventionThromboprophylaxis / Traumas / Venous Thromboembolism1
4CompletedPreventionAcute Coronary Syndromes (ACS)1
4CompletedPreventionAcute Ischemic Stroke (AIS)1
4CompletedPreventionAnticoagulants / BMI >30 kg/m2 / Thrombosis, Venous1
4CompletedPreventionAntiphospholipid Syndrome / Recurrent Miscarriages1
4CompletedPreventionBrain Injury / Thrombosis, Venous1
4CompletedPreventionDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolic Diseases1
4CompletedPreventionFemur Head Necrosis / Fracture of Neck of Femur / Osteoarthritis, Hip1
4CompletedPreventionImpaired Renal Function / Venous Thromboembolism1
4CompletedPreventionInflammatory Reaction1
4CompletedPreventionVenous Thromboembolism2
4CompletedTreatmentAcute Coronary Syndromes (ACS)1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Factor X1
4CompletedTreatmentAcute Illness1
4CompletedTreatmentAdverse Effect of Anticoagulants / Deep Vein Thrombosis (DVT) / Thrombosis, Venous1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentBruises1
4CompletedTreatmentCoronary Heart Disease (CHD)1
4CompletedTreatmentHaemorrhage / Nonvalvular Atrial Fibrillation / Strokes / Thrombo-embolism1
4CompletedTreatmentMechanical Valve Replacement / Warfarin Therapy1
4CompletedTreatmentNonvalvular Atrial Fibrillation1
4CompletedTreatmentThrombosis, Venous1
4CompletedTreatmentUnexplained Infertility1
4Not Yet RecruitingPreventionKnee Osteoarthritis (Knee OA)1
4Not Yet RecruitingPreventionVenous Thromboembolism1
4RecruitingBasic ScienceAnticoagulants and Bleeding Disorders / General Surgery / Regional Anesthesia Morbidity1
4RecruitingPreventionAntiphospholipid Syndrome / Recurrent Miscarriages1
4RecruitingPreventionDeep Venous Thrombosis / Prophylaxis of Pulmonary embolism1
4RecruitingPreventionPrimary Percutaneous Coronary Intervention1
4RecruitingPreventionProphylaxis of Pulmonary embolism / Thromboprophylaxis / Venous Thromboembolism1
4RecruitingPreventionTraumatic Brain Injury (TBI) / VTE (Venous Thromboembolism)1
4RecruitingTreatmentCoronary Artery Disease / Percutaneous Coronary Intervention1
4RecruitingTreatmentInfertility Female1
4TerminatedPreventionDeep Vein Thrombosis (DVT)1
4TerminatedTreatmentUnstable Angina (UA)1
4Unknown StatusPreventionGeneral Surgery / Prevention / Thrombosis1
4Unknown StatusPreventionHemodialysis Patients1
4Unknown StatusPreventionIntracerebral Hemorrhage1
4Unknown StatusPreventionThromboembolism1
4Unknown StatusTreatmentAbortions spontaneous / Pregnancy1
4Unknown StatusTreatmentBMI >30 kg/m21
4Unknown StatusTreatmentCoronary Artery Disease1
4Unknown StatusTreatmentProphylaxis of Pulmonary embolism / Thrombosis, Venous1
Not AvailableActive Not RecruitingPreventionDeep Venous Thrombosis / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
Not AvailableActive Not RecruitingTreatmentCancer Patients First-ever Acute Ischemic Stroke1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableMalignant Lymphomas / Thromboembolism / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedNot AvailableThrombosis, Venous1
Not AvailableCompletedPreventionAcute Myocardial Infarction (AMI) / Coronary Artery Disease1
Not AvailableCompletedPreventionDeep Vein Thrombosis of Lower Limb / Haemorrhage / Prophylaxis of Pulmonary embolism1
Not AvailableCompletedPreventionEnd Stage Renal Failure on Dialysis1
Not AvailableCompletedPreventionFetal Demise / Intrauterine Growth Retardation / Preeclampsia / Premature separation of placenta / Thromboembolism1
Not AvailableCompletedPreventionVenous Thromboembolic Diseases1
Not AvailableCompletedSupportive CareBone Metastases / Musculoskeletal Cancer / Soft Tissue Sarcoma (STS) / Thromboembolism1
Not AvailableCompletedTreatmentCoronary Artery Bypass Grafting (CABG) Surgery / Coronary Heart Disease (CHD)1
Not AvailableCompletedTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism1
Not AvailableCompletedTreatmentVenous Thromboembolism1
Not AvailableNo Longer AvailableNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableNot Yet RecruitingPreventionHemorrhage, Gastrointestinal / Post Polypectomy Bleeding in Anticoagulated Patients1
Not AvailableNot Yet RecruitingTreatmentAcute Exacerbation Copd / Venous Thromboembolism1
Not AvailableRecruitingNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableRecruitingHealth Services ResearchNeoplasms / Thrombosis, Venous1
Not AvailableRecruitingPreventionDeep Vein Thrombosis (DVT) / Other Specified Risk Factors in Pregnancy / Perioperative/Postoperative Complications / Prophylaxis of Pulmonary embolism / Thrombophilia Associated With Pregnancy / Thrombosis, Venous1
Not AvailableRecruitingPreventionTraumatic Intracranial Hemorrhage1
Not AvailableRecruitingTreatmentBlood Clots / Cancers / Deep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
Not AvailableTerminatedPreventionThrombosis, Venous1
Not AvailableTerminatedTreatmentAcute Ischemic Stroke (AIS)1
Not AvailableUnknown StatusPreventionDeep Vein Thrombosis (DVT) / General Surgery / Thromboembolic Events / Traumas1
Not AvailableUnknown StatusPreventionThrombosis1
Not AvailableUnknown StatusPreventionTraumatic Intracranial Hemorrhage1
Not AvailableUnknown StatusSupportive CareBlood Loss / Osteoarthritis, Hip1
Not AvailableUnknown StatusTreatmentHeart; Complications, Valve, Prosthesis / Pregnancy1
Not AvailableWithdrawnNot AvailableAcute Coronary Syndromes (ACS) / Non ST Elevation Myocardial Infarction / ST Elevation Myocardial Infarction / Unstable Angina (UA)1
Not AvailableWithdrawnPreventionLower Extremity Deep Venous Thrombosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
InjectionSubcutaneous100 mg/mL
InjectionSubcutaneous120 mg/.8mL
InjectionSubcutaneous150 mg/mL
InjectionSubcutaneous30 mg/.3mL
InjectionSubcutaneous300 mg/3mL
InjectionSubcutaneous40 mg/.4mL
InjectionSubcutaneous60 mg/.6mL
InjectionSubcutaneous80 mg/.8mL
Injection, solutionIntravenous; Subcutaneous100 mg/mL
Injection, solutionIntravenous; Subcutaneous120 mg/.8mL
Injection, solutionIntravenous; Subcutaneous150 mg/mL
Injection, solutionIntravenous; Subcutaneous30 mg/.3mL
Injection, solutionIntravenous; Subcutaneous40 mg/.4mL
Injection, solutionIntravenous; Subcutaneous60 mg/.6mL
Injection, solutionIntravenous; Subcutaneous80 mg/.8mL
InjectionIntravenous; Subcutaneous100 mg/mL
InjectionIntravenous; Subcutaneous120 mg/.8mL
InjectionIntravenous; Subcutaneous150 mg/mL
InjectionIntravenous; Subcutaneous30 mg/.3mL
InjectionIntravenous; Subcutaneous300 mg/3mL
InjectionIntravenous; Subcutaneous40 mg/.4mL
InjectionIntravenous; Subcutaneous60 mg/.6mL
InjectionIntravenous; Subcutaneous80 mg/.8mL
SolutionSubcutaneous100 mg
SolutionSubcutaneous30 mg
SolutionSubcutaneous40 mg
SolutionSubcutaneous60 mg
SolutionSubcutaneous80 mg
SolutionSubcutaneous120 mg
SolutionSubcutaneous150 mg
SolutionSubcutaneous90 mg
SolutionIntravenous; Subcutaneous100 mg
Prices
Unit descriptionCostUnit
Lovenox 300 mg/3ml Solution 3ml Vial281.47USD vial
Lovenox 150 mg/ml Solution 1ml Syringe140.94USD syringe
Lovenox 100 mg/ml Solution 1ml Syringe93.93USD syringe
Lovenox 80 mg/0.8ml Solution 0.8ml Syringe75.14USD syringe
Lovenox 60 mg/0.6ml Solution 0.6ml Syringe56.36USD syringe
Lovenox 40 mg/0.4ml Solution 0.4ml Syringe37.53USD syringe
Lovenox Hp (0.8Ml/1Ml Syringe) 150 mg/ml Syringe34.63USD syringe
Lovenox 30 mg/0.3ml Solution 0.3ml Syringe28.15USD syringe
Lovenox (0.4 - 1 Ml Syringe) 100 mg/ml Syringe23.09USD syringe
Lovenox 100 mg/ml23.09USD syringe
Lovenox (0.3 Ml Syringe) 30 mg/syr Syringe6.97USD syringe
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5389618No1995-02-142012-02-14Us
CA2045433No2002-07-302011-06-25Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility> 200 mg/mLNot Available
logP-13.2Not Available
Predicted Properties
Not Available
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9215
Blood Brain Barrier-0.8366
Caco-2 permeable-0.6496
P-glycoprotein substrateNon-substrate0.698
P-glycoprotein inhibitor INon-inhibitor0.5818
P-glycoprotein inhibitor IINon-inhibitor0.9771
Renal organic cation transporterNon-inhibitor0.9454
CYP450 2C9 substrateNon-substrate0.6694
CYP450 2D6 substrateNon-substrate0.8196
CYP450 3A4 substrateNon-substrate0.5842
CYP450 1A2 substrateNon-inhibitor0.8157
CYP450 2C9 inhibitorNon-inhibitor0.771
CYP450 2D6 inhibitorNon-inhibitor0.8869
CYP450 2C19 inhibitorNon-inhibitor0.7655
CYP450 3A4 inhibitorNon-inhibitor0.9194
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9232
Ames testNon AMES toxic0.5957
CarcinogenicityNon-carcinogens0.694
BiodegradationNot ready biodegradable0.851
Rat acute toxicity2.3846 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Non-inhibitor0.7157
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
Gene Name
SERPINC1
Uniprot ID
P01008
Uniprot Name
Antithrombin-III
Molecular Weight
52601.935 Da
References
  1. Peng K, Wang C, Pang BS, Yang YH: [Effects of thrombolysis and anticoagulation on the functions of vascular endothelial cells and coagulation and fibrinolysis in patients with pulmonary thromboembolism]. Zhonghua Jie He He Hu Xi Za Zhi. 2005 Sep;28(9):596-9. [PubMed:16207425]
  2. Lee S, Gibson CM: Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May;5(3):387-99. [PubMed:17489664]
  3. Bisio A, Vecchietti D, Citterio L, Guerrini M, Raman R, Bertini S, Eisele G, Naggi A, Sasisekharan R, Torri G: Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thromb Haemost. 2009 Nov;102(5):865-73. doi: 10.1160/TH09-02-0081. [PubMed:19888521]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. Graff J, Picard-Willems B, Harder S: Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther. 2007 Apr;45(4):237-43. [PubMed:17474542]
  2. Berges A, Laporte S, Epinat M, Zufferey P, Alamartine E, Tranchand B, Decousus H, Mismetti P: Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol. 2007 Oct;64(4):428-38. Epub 2007 May 17. [PubMed:17509040]
  3. Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G: Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol. 2005 Oct;60(4):364-73. [PubMed:16187968]
  4. Dalmora SL, Junior LB, Schmidt CA, Vaccari SF, Oliveira PR, Codevilla CF: Validation of the anti-factor Xa assay for the potency assessment of enoxaparin in pharmaceutical formulations. J AOAC Int. 2004 Nov-Dec;87(6):1305-8. [PubMed:15675440]
  5. Paige JT, Gouda BP, Gaitor-Stampley V, Scalia PG, Klainer TE, Raum WJ, Martin LF: No correlation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass. Surg Obes Relat Dis. 2007 Jul-Aug;3(4):469-75. Epub 2007 Jun 12. [PubMed:17567541]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Rudolph TK, Rudolph V, Witte A, Klinke A, Szoecs K, Lau D, Heitzer T, Meinertz T, Baldus S: Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. Int J Cardiol. 2010 Apr 1;140(1):42-7. doi: 10.1016/j.ijcard.2008.10.035. Epub 2008 Dec 2. [PubMed:19049846]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18